1.
Pitfalls in health-economic evaluations: the case of cost-effectiveness of prophylactic implantable cardioverter-defibrillator therapy in Belgium
2.
3.
4.
5.
6.
7.
Introducing the non-invasive prenatal test for trisomy 21 in Belgium: a cost-consequences analysis
Effectiveness of catheter ablation of atrial fibrillation in Belgian practice: a cohort analysis on administrative data
8.
9.
Health technology assessment on catheter ablation of atrial fibrillation in Belgium
First- and second-line bevacizumab in ovarian cancer: A Belgian cost-utility analysis
A cost-utility analysis of transcatheter aortic valve implantation in Belgium: focusing on a well-defined and identifiable population
An evaluation of managed entry agreements in Belgium: A system with threats and (high) potential if properly applied